The insulin-like growth axis in patients with autoimmune thyrotoxicosis: Effect of antithyroid drug treatment

Growth Hormone and IGF Research

Volumn 14, Issue 3, 2004, Pages 235-244

  Zimmermann Belsing, T ^a   Juul, A ^b   Juul Holst, J ^c   Feldt Rasmussen, U ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Body composition; Graves' disease; Insulin like growth factor; Leptin; Thyroid autoantibodies; Thyroid disease

Indexed keywords

ANTITHYROID AGENT; INSULIN; LEPTIN; LIOTHYRONINE; PROTEIN SUBUNIT; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THIAMAZOLE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DIET RESTRICTION; FEMALE; FOLLOW UP; GENDER; GRAVES DISEASE; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN RELEASE; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; THYROID FUNCTION; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TIME;

EID: 2542469702     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ghir.2003.12.015     Document Type: Article

References (74)

1. M. Binoux, C. Lassarre, N. Hardouin, Somatomedin production by rat liver in organ culture III studies on the release of insulin-like growth factor and its carrier protein measured by radioligand assays. Effects of growth hormone, insulin and cortisol, Acta Endocrinol. (Copenh.) 99 (1982) 422-430.
2. I.D. Phillips, E. Arany, A.J. Strain, V.K. Han, D.J. Hill, Rapid clearance of insulin-like growth factor (IGF)-binding protein species from blood and an associated fall in circulating IGF-I following partial hepatectomy in the rat, J. Endocrinol. 137 (1993) 271-280.
3. K.S. Langford, J.P. Miell, The insulin-like growth factor-I/binding protein axis: physiology, pathophysiology and therapeutic manipulation, Eur. J. Clin. Invest. 23 (1993) 503-516.
4. M. Binoux, P. Hossenlopp, S. Hardouin, D. Seurin, C. Lassarre, M. Gourmelen, Somatomedin (insulin-like growth factors)-binding proteins. Molecular forms and regulation, Horm. Res. 24 (1986) 141-151.
5. H.P. Guler, J. Zapf, E.R. Froesch, Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults, N. Engl. J. Med. 317 (1987) 137-140.
6. Z. Kachra, I. Barash, C. Yannopoulos, M.N. Khan, H.J. Guyda, B.I. Posner, The differential regulation by glucagon and growth hormone of insulin-like growth factor (IGF)-I and IGF binding proteins in cultured rat hepatocytes, Endocrinology 128 (1991) 1723-1730.
7. J.C. Schwander, C. Hauri, J. Zapf, E.R. Froesch, Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status, Endocrinology 113 (1983) 297-305.
8. W.S. Cohick, DR. Clemmons, The insulin-like growth factors, Annu. Rev. Physiol. 55 (1993) 131-153.
9. R.W. Furlanetto, The somatomedin C binding protein: evidence for a heterologous subunit structure, J. Clin. Endocrinol. Metab. 51 (1980) 12-19.
10. R.C. Baxter, Insulin-like growth factor binding proteins in the human circulation: a review, Horm. Res. 42 (1994) 140-144.
11. F. Liu, R.L. Hintz, A. Khare, R.P. Diaugustine, D.R. Powell, P.D. Lee, Immunoblot studies of the IGF-related acid-labile subunit, J. Clin. Endocrinol. Metab. 79 (1994) 1883-1886.
12. E. Arany, S. Afford, A.J. Strain, P.J. Winwood, M.J. Arthur, D.J. Hill, Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver, J. Clin. Endocrinol. Metab. 79 (1994) 1871-1876.
13. E. Chin, J. Zhou, J. Dai, R.C. Baxter, C.A. Bondy, Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex, Endocrinology 134 (1994) 2498-2504.
14. R.C. Baxter, Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex, J. Clin. Endocrinol. Metab. 67 (1988) 265-272.
15. R.C. Baxter, J.L. Martin, V.A. Beniac, High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum, J. Biol. Chem. 264 (1989) 11843-11848.
16. R.C. Baxter, Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex, J. Clin. Endocrinol. Metab. 70 (1990) 1347-1353.
17. W.F. Blum, M.B. Ranke, Insulin-like growth factor binding proteins (IGFBPs) with special reference to IGFBP-3, Acta Paediatr. Scand. Suppl. 367 (1990) 55-62.
18. W.F. Blum, K. Albertsson-Wikland, S. Rosberg, M.B. Ranke, Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protem-3 reflect spontaneous growth hormone secretion, J. Clin. Endocrinol. Metab. 76 (1993) 1610-1616.
19. J.C. Ramos-Dias, F. Pimentel-Filho, A.F. Reis, A.M. Lengyel, Different growth hormone (GH) response to GH-releasing peptide and GH-releasing hormone in hyperthyroidism, J. Clin. Endocrinol. Metab. 81 (1996) 1343-1346.
20. J.C. Ramos-Dias, M. Yateman, C. Camacho-Hubner, A. Grossman, A.M. Lengyel, Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone, Clin. Endocrinol. (Oxf.) 43 (1995) 583-589.
21. J.C. Ramos-Dias, A.M. Lengyel, Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients, Clin. Endocrinol. (Oxf.) 51 (1999) 461-467.
22. A. Giustina, A.R. Bussi, F. Legati, S. Bossoni, M. Licini, M. Schettino, F. Zuccato, W.B. Wehrenberg, Galanin does not affect the growth hormone-releasing hormone-stimulated growth hormone secretion in patients with hyperthyroidism, Acta Endocrinol. (Copenh.) 127 (1992) 504-508.
23. A. Giustina, W.B. Wehrenberg, Influence of thyroid hormones on the regulation of growth hormone secretion, Eur. J. Endocrinol. 133 (1995) 646-653.
24. R. Valcavi, C. Dieguez, M. Zini, C. Muruais, F. Casanueva, I. Portioli, Influence of hyperthyroidism on growth hormone secretion, Clin. Endocrinol. (Oxf.) 38 (1993) 515-522.
25. A. Iranmanesh, G. Lizarralde, M.L. Johnson, J.D. Veldhuis, Nature of altered growth hormone secretion in hyperthyroidism, J. Clin. Endocrinol. Metab. 72 (1991) 108-115.
26. J.C. Lovejoy, S.R. Smith, G.A. Bray, J.D. Veldhuis, J.C. Rood, R. Tulley, Effects of experimentally induced mild hyperthyroidism on growth hormone and insulin secretion and sex steroid levels in healthy young men, Metabolism 46 (1997) 1424-1428.
27. F. Tosi, P. Moghetti, R. Castello, C. Negri, E. Bonora, M. Muggeo, Early changes in plasma glucagon and growth hormone response to oral glucose in experimental hyperthyroidism, Metabolism 45 (1996) 1029-1033.
28. P. Iglesias, C. Bayon, J. Mendez, P.G. Gancedo, C. Grande, J.J. Diez, Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction, Thyroid 11 (2001) 1043-1048.
29. M.R. Thomas, J.P. Miell, A.M. Taylor, R.J. Ross, J.R. Arnao, D.E. Jewitt, A.M. McGregor, Endocrine and cardiac paracrine actions of insulin-like growth factor-I (IGF-I) during thyroid dysfunction in the rat: is IGF-I implicated in the mechanism of heart weight/body weight change during abnormal thyroid function?, J. Mol. Endocrinol. 10 (1993) 313-323.
30. J.P. Miell, A.M. Taylor, M. Zini, H.G. Maheshwari, R.J. Ross, R. Valcavi, Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone, J. Clin. Endocrinol. Metab. 76 (1993) 950-955.
31. W.M. Wan Nazaimoon, B.A. Khalid, Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves' disease, Horm. Metab. Res. 30 (1998) 213-216.
32. P. Lakatos, J. Foldes, Z. Nagy, I. Takacs, G. Speer, C. Horvath, S. Mohan, D.J. Baylink, P.H. Stern, Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism, Thyroid 10 (2000) 417-423.
33. T. Inukai, K. Takanashi, K. Takebayashi, Y. Fujiwara, K. Tayama, Y. Takemura, Thyroid hormone modulates insulin-like growth factor-I (IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases, Horm. Metab. Res. 31 (1999) 576-579.
34. L.L. Co Ng, C.H. Lang, A. Bereket, A. Purandare, A. Smaldone, T.A. Wilson, Effect of hyperthyroidism on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in adolescent children, J. Pediatr. Endocrinol. Metab. 13 (2000) 1073-1080.
35. K. Nanto-Salonen, H.L. Muller, A.R. Hoffman, T.H. Vu, R.G. Rosenfeld, Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated, Endocrinology 132 (1993) 781-788.
36. A. Morovat, M.J. Dauncey, Effects of thyroid status on insulin-like growth factor-I, growth hormone and insulin are modified by food intake, Eur. J. Endocrinol. 138 (1998) 95-103.
37. J. Frystyk, H. Gronbaek, C. Skjaerbaek, A. Flyvbjerg, Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats, Am. J. Physiol. 269 (1995) E840-E845.
38. M. Angervo, M. Tiihonen, P. Leinonen, M. Valimaki, M. Seppala, Thyroxine treatment increases circulating levels of insulin-like growth factor binding protein-1: a placebo-controlled study, Clin. Endocrinol. (Oxf.) 38 (1993) 547-551.
39. L. Lonn, K. Stenlof, M. Ottosson, A.K. Lindroos, E. Nystrom, L. Sjostrom, Body weight and body composition changes after treatment of hyperthyroidism, J. Clin. Endocrinol. Metab. 83 (1998) 4269-4273.
40. C. Kirkegaard, J. Faber, The role of thyroid hormones in depression, Eur. J. Endocrinol. 138 (1998) 1-9.
41. H. Perrild, J.M. Hansen, K. Arnung, P.Z. Olsen, U. Danielsen, Intellectual impairment after hyperthyroidism, Acta Endocrinol. (Copenh.) 112 (1986) 185-191.
42. T. Zimmermann-Belsing, M. Dreyer, J.J. Holst, U. Feldt-Rasmussen, The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects, Clin. Endocrinol. (Oxf.) 49 (1998) 589-595.
43. M. Schott, J. Feldkamp, C. Bathan, R. Fritzen, W.A. Scherbaum, J. Seissler, Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation, Horm. Metab. Res. 32 (2000) 429-435.
44. C. Massart, J. Orgiazzi, D. Maugendre, Clinical validity of a new commercial method for detection of TSH-receptor binding anti-bodies in sera from patients with Graves' disease treated with antithyroid drugs, Clin. Chim. Acta 304 (2001) 39-47.
45. U. Feldt-Rasmussen, M. Hoier-Madsen, K. Bech, M. Blichert-Toft, H. Bliddal, J. Date, B. Danneskiold-Samsoe, L. Hegedus, E. Hippe, P.J. Hornnes, Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases, Autoimmunity 9 (1991) 245-254.
46. Z. Ma, R.L. Gingerich, J.V. Santiago, S. Klein, C.H. Smith, M. Landt, Radioimmunoassay of leptin in human plasma, Clin. Chem. 42 (1996) 942-946.
47. K. Hosoda, H. Masuzaki, Y. Ogawa, T. Miyawaki, J. Hiraoka, I. Hanaoka, A. Yasuno, T. Nomura, Y. Fujisawa, Y. Yoshimasa, S. Nishi, Y. Yamori, K. Nakao, Development of radioimmunoassay for human leptin, Biochem. Biophys. Res. Commun. 221 (1996) 234-239.
48. P.K. Nielsen, J. Ladefoged, K. Olgaard, Lean body mass by dual energy X-ray absorptiometry (DEXA) and by urine and dialysate creatinine recovery in CAPD and pre-dialysis patients compared to normal subjects, Adv. Perit. Dial. 10 (1994) 99-103.
49. J. Haarbo, A. Gotfredsen, C. Hassager, C. Christiansen, Validation of body composition by dual energy X-ray absorptiometry (DEXA), Clin. Physiol. 11 (1991) 331-341.
50. A. Gotfredsen, L. Baeksgaard, J. Hilsted, Body composition analysis by DEXA by using dynamically changing samarium filtration, J. Appl. Physiol. 82 (1997) 1200-1209.
51. A. Juul, P. Bang, N.T. Hertel, K. Main, P. Dalgaard, K. Jorgensen, J. Muller, K. Hall, N.E. Skakkebaek, Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index, J. Clin. Endocrinol. Metab. 78 (1994) 744-752.
52. A. Juul, K. Holm, K.W. Kastrup, S.A. Pedersen, K.F. Michaelsen, T. Scheike, S. Rasmussen, J. Muller, N.E. Skakkebaek, Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency, J. Clin. Endocrinol. Metab. 82 (1997) 2497-2502.
53. A. Juul, S. Moller, E. Mosfeldt-Laursen, M.H. Rasmussen, T. Scheike, S.A. Pedersen, K.W. Kastrup, H. Yu, J. Mistry, S. Rasmussen, J. Muller, J. Henriksen, N.E. Skakkebaek, The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency, J. Clin. Endocrinol. Metab. 83 (1998) 440-415.
54. A. Juul, P. Dalgaard, W.F. Blum, P. Bang, K. Hall, K.F. Michaelsen, J. Muller, N.E. Skakkebaek, Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation, J. Clin. Endocrinol. Metab. 80 (1995) 2534-2542.
55. A. Juul, K. Main, W.F. Blum, J. Lindholm, M.B. Ranke, N.E. Skakkebaek, The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients, Clin. Endocrinol. (Oxf.) 41 (1994) 85-93.
56. H. Yu, J. Mistry, M.J. Nicar, M.J. Khosravi, A. Diamandis, J. van Doorn, A. Juul, Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation, J. Clin. Lab. Anal. 13 (1999) 166-172.
57. B.L. Langdahl, A.G. Loft, E.F. Eriksen, L. Mosekilde, P. Charles, Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy, Thyroid 6 (1996) 161-168.
58. A. Juul, S.A. Pedersen, S. Sorensen, K. Winkler, J.O. Jorgensen, J.S. Christiansen, N.E. Skakkebaek, Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset, Eur. J. Endocrinol. 131 (1994) 41-49.
59. T. Zimmermann-Belsing, G. Brabant, J.J. Holst, U. Feldt-Rasmussen, Circulating leptin and thyroid dysfunction, Eur. J. Endocrinol. 149 (2003) 257-271.
60. H. Tada, Y. Watanabe, Y. Futakuchi, N. Amino, Change in serum concentration of insulin-like growth factor II (IGF-II) in patients with thyroid disease, Endocr. J. 41 (1994) 541-545.
61. P.J. Hsiao, J.H. Tsai, Increased insulin-like growth factor-1 receptors in thyroid tissues of Graves' disease, J. Formos. Med. Assoc. 93 (1994) 925-932.
62. K. Cissewski, M. Wolf, A.C. Moses, Characterization of insulin-like growth factor receptors in human thyroid tissue, Receptor 2 (1992) 145-153.
63. M.J. Muller, H.J. Seitz, Thyroid hormone action on intermediary metabolism. Part III. Protein metabolism in hyper- and hypothyroidism, Klin. Wochenschr. 62 (1984) 97-102.
64. J.O. Jorgensen, S.A. Pedersen, P. Laurberg, J. Weeke, N.E. Skakkebaek, J.S. Christiansen, Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism, J. Clin. Endocrinol. Metab. 69 (1989) 1127-1132.
65. J. Svensson, B. Carlsson, L.M. Carlsson, J.O. Jansson, B.A. Bengtsson, Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677, Clin. Endocrinol. (Oxf.) 50 (1999) 451-456.
66. M.W. Schwartz, S.C. Woods, D. Porte Jr., R.J. Seeley, D.G. Baskin, Central nervous system control of food intake, Nature 404 (2000) 661-671.
67. B.B. Lowell, B.M. Spiegelman, Towards a molecular understanding of adaptive thermogenesis, Nature 404 (2000) 652-660.
68. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue, Nature 372 (1994) 425-432.
69. M.A. Pelleymounter, M.J. Cullen, M.B. Baker, R. Hecht, D. Winters, T. Boone, F. Collins, Effects of the obese gene product on body weight regulation in oblob mice, Science 269 (1995) 540-543.
70. C.S. Mantzoros, S.J. Moschos, Leptin: in search of role(s) in human physiology and pathophysiology, Clin. Endocrinol. (Oxf.) 49 (1998) 551-567.
71. G. Fruhbeck, S.A. Jebb, A.M. Prentice, Leptin: physiology and pathophysiology, Clin. Physiol. 18 (1998) 399-419.
72. J.S. Flier, M. Harris, A.N. Hollenberg, Leptin, nutrition, and the thyroid: the why, the wherefore, and the wiring, J. Clin. Invest. 105 (2000) 859-861.
73. K. Bech, P. Damsbo, E. Eldrup, H. Beck-Nielsen, M.E. Roder, S.G. Hartling, A. Volund, S. Madsbad, Beta-cell function and glucose and lipid oxidation in Graves' disease, Clin. Endocrinol. (Oxf.) 44 (1996) 59-66.
74. J.M. Fernandez-Real, M.L. Granada, A. Ruzafa, R. Casamitjana, W. Ricart, Insulin sensitivity and secretion influence the relationship between growth hormone-binding-protein and leptin, Clin. Endocrinol. (Oxf.) 52 (2000) 159-164.